As a result, Salvigenin may dampen HCC cell proliferation, migration, and invasion and weaken cell glycolysis and chemoresistance mainly by modulating the PI3K/AKT/GSK-3β pathway. The gene discussed is AKT1; the disease is hepatocellular carcinoma.